Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 25 NOVEMBER 2026 AND CHANGE OF AUDITOR

Reference is made to the circular (the "**Circular**") of Grand Pharmaceutical Group Limited (the "**Company**") dated 5 November 2026 in relation to the Proposed Change of Auditors and the notice of special general meeting (the "**Notice**") contained therein. Unless stated otherwise, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS

The Board announces that all the resolutions proposed were duly passed by way of poll at the SGM of the Company held on 25 November 2026.

As at the date of the SGM, the total number of issued shares in the Company was 3,549,571,148 Shares, which represents the total number of Shares entitling the Shareholders to vote for or against all the resolutions at the SGM.

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the SGM pursuant to Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the resolutions at the SGM. None of the Shareholders had stated his/her/its intention in the Circular to vote against the resolutions or to abstain from voting at the SGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, has been appointed as the scrutineer for the SGM in connection with the counting of votes.

The poll results in respect of all the resolutions proposed at the SGM were as follows:

EXTRAORDINARY RESOLUTION		Number of Shares represented by votes cast (and percentage of total number of Shares represented by votes cast)	
		For	**Against**
(1)	To terminate the appointment of HLB as the auditor of the Company with immediate effect after the conclusion of the Meeting.	2,038,515,763 (99.96%)	723,051 (0.04%)
ORDINARY RESOLUTION		Number of Shares represented by votes cast (and percentage of total number of Shares represented by votes cast)	
		For	**Against**
(2)	Conditional upon the passing of the resolution numbered 1 above, to appoint Deloitte as the auditor of the Company in place of HLB with immediate effect after the conclusion of the Meeting to hold office until the conclusion of the forthcoming annual general meeting of the Company, and to authorise the Board to fix the remuneration of Deloitte.	1,994,482,243 (97.81%)	44,756,571 (2.19%)

Note: Full text of the resolutions is set out in the Notice.

As not less than two-thirds of the votes were cast in favour of the resolution numbered 1, such resolution was duly passed by the Shareholders as an extraordinary resolution of the Company at the SGM. As more than half of the votes were cast in favour of the resolution numbered 2, such resolution was duly passed by the Shareholders as an ordinary resolution of the Company at the SGM.

All Directors attended the SGM either in person or electronically.

CHANGE OF AUDITOR

Following the approval of the Shareholders at the SGM, with effect from the conclusion of the SGM, the appointment of HLB as the Auditor has been terminated and Deloitte has been appointed as the new Auditor for the year ending 31 December 2026 to fill the casual vacancy following the Proposed Termination and to hold office until the conclusion of the next annual general meeting of the Company.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 25 November 2026

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*